# Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer

> **NCT00101114** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 55 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Cancer
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** sorafenib tosylate
- **BIOLOGICAL:** recombinant interferon alfa-2b
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00101114
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2006-05
- **Final completion:** —
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101114, "Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00101114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*